Selexis SA and SpyBiotech have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV)
BITT will leverage Selexis’ suite of proprietary modular technologies designed to overcome the complex challenges of protein-expression and deliver the high performance research cell banks necessar...
Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.
ABSCI CLOSES $15.4 M IN SERIES D FUNDING TO ACCELERATE GROWTH AND SCALE DISRUPTIVE PROTEIN PRINTINGTM TECHNOLOGY, ANNOUNCES EXCLUSIVE CO-MARKETING PARTNERSHIP WITH KBI BIOPHARMA
Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multi...
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and combination therapies
4 of 10
Receive JSR Life Sciences news on your RSS reader.